DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0293.086 A1 MESSMER Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0293.086 A1 MESSMER Et Al US 20150293O86A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0293.086 A1 MESSMER et al. (43) Pub. Date: Oct. 15, 2015 (54) LATERAL FLOW IMMUNOASSAY Publication Classification (71) Applicant: ABREOS BIOSCIENCES, INC., San (51) Int. Cl. Diego, CA (US) GOIN33/543 (2006.01) GOIN33/68 (2006.01) (72) Inventors: Bradley Todd MESSMER, San Diego, GOIN33/94 (2006.01) CA (US); Peter HABERZ, San Diego, GOIN33/558 (2006.01) CA (US) (52) U.S. Cl. CPC ........ G0IN33/54386 (2013.01); G0IN33/558 (21) Appl. No.: 14/686,578 (2013.01); G0IN33/6854 (2013.01); G0IN 33/94 (2013.01) (22) Filed: Apr. 14, 2015 (57) ABSTRACT Disclosed is a test device for determining the presence or Related U.S. Application Data integrity of a biologic comprising a sample pad for receiving the biologic, a conjugate pad, and a test membrane compris (60) Provisional application No. 61/979,123, filed on Apr. ing at least one test line comprising an immobilized mime 14, 2014. tope, and methods of using the same. Caitro line 3 Wicking Pad oitris: i.e : C:- Qigg Conjugate Paci a Kagga alg3 Fc nanoA Sampie Pad Contro: itse 2 test ine catbids finsatose peptive Flow & 2. --- i wog of active Á: wirging as active A: wroig Aix wigg. A {{ A, ikey 33 g(3 { A, xey is a g3 c{3}{338c: six c:33:33.8d 38.33 to attit.xy 88 artiaoriy assay faiec Patent Application Publication Oct. 15, 2015 Sheet 1 of 6 US 2015/029.308.6 A1 FGURE 1 Cottro tie 3 Wicking Pad Cartoire 3. & EigG Certigate Pad &Kaga cigg FC and As Sarpia Pad Corirai :38 2. Best & catalis time toge peptide Fow - c w i SS 8.338; 8.3: ... ', wog 8* is active A: wrog (; ; ;8&tive YA &oig A. weig A. 3 Ai, key 3.3 g3 to Ab, iikey harai ig3 coatiated Air coatiated & 8 at:38 y 83;{i}{3xy assay faiei assay failed Patent Application Publication Oct. 15, 2015 Sheet 2 of 6 US 2015/029.308.6 A1 3 *33 88 *33 Ritaxia gins Patent Application Publication Oct. 15, 2015 Sheet 3 of 6 US 2015/029.308.6 A1 FGURE 3 ::::::::::::::::::::8: Patent Application Publication Oct. 15, 2015 Sheet 4 of 6 US 2015/029.308.6 A1 FIGURE 4 Patent Application Publication Oct. 15, 2015 Sheet 5 of 6 US 2015/029.3086 A FIGURE 5 Test line 8 83. 8 :8 Patent Application Publication Oct. 15, 2015 Sheet 6 of 6 US 2015/029.3086 A FIGURE 6 Test line 3 Test line 2 US 2015/0293O86 A1 Oct. 15, 2015 LATERAL FLOW IMMUNOASSAY bilized mimetope, (b) determining whether at least one test line undergoes a color change, (c) determining, based on the RELATED APPLICATIONS color change, the activity of the biologic. 0001. The present application claims the benefit of U.S. 0009 Disclosed herein is a kit comprising (a) a test device Provisional Application Ser. No. 61/979,123, filed on Apr. 14, for determining the integrity of a biologic, the test device 2014, by Bradley T. MESSMER et al. and entitled “LAT comprising a sample receiving pad, a conjugatepad, and a test ERAL FLOW IMMUNOASSAY, the entire disclosure of membrane, the test membrane further comprising at least one which is incorporated herein by reference, including the test line and at least one control line, and (b) instructions for drawings. use thereof. BRIEF DESCRIPTION OF THE DRAWINGS GOVERNMENT RIGHTS 0010 FIG. 1 illustrates one embodiment of the lateral flow 0002 The subject matter disclosed herein was made with assay disclosed herein. The top panel illustrates a schematic government support under grants 1R41CA192697-01 and of the prototype. A drop of the biologic sample is placed on a 1R43CA183241-01 awarded by the National Institutes of sample pad and is wicked through the device. After binding Health Small Business Innovation Research (NIH-SBIR). the secondary detection antibody, conjugated to gold, the The government has certain rights in the disclosed subject sample encounters the peptide, anti-light chain, and anti matter. secondary capture agents. The bottom panel illustrates pos sible outcome matrix for an antibody that is known to possess FIELD OF THE INVENTION a kappa light chain. 0003. The present invention is in the field of test devices, 0011 FIG. 2 (A) illustrates one embodiment of the lateral and more specifically in the field of lateral flow test devices. flow assay validating that rituximab binding mimetope pep tide function in immunoassays and competes with the native BACKGROUND OF THE DISCLOSURE antigen (CD20). FIG. 2 (A) is a standard curve for rituximab by peptide based ELISA. Biotinylated peptides are bound 0004 Biologics are valuable therapeutics for treating can onto neutravidin coated ELISA plates. Rituximab is diluted in cers and other diseases. As they are among the most expensive TBST. Each value shows the mean (S.D.) of triplicates. The pharmaceuticals produced and increasingly prescribed, there solid line indicates the mean of the buffer control and the have been a growing number of incidents involving counter dashed line represents the mean +10 times the SD of the feit biologics, such as counterfeit antibodies. These econom buffer control. ics create a considerable incentive for counterfeit or other (0012 FIG. 2 (B) illustrates peptide inhibition of Chronic deceptions. The problem of counterfeit medications is grow Lymphocytic Leukemia (CLL) cell staining. Fluorescently ing rapidly. The Center for Medicines in the Public Interest labeled rituximab is incubated with primary CLL cells and estimates that the worldwide trade for counterfeit medicines evaluated by flow cytometry (solid line). Weak staining for exceeds S75 billion. This number is S25 billion more than the CD20 was observed because CLL cells have low levels of illicit drug trade. Therefore, there is a concern that organized CD20. When peptide RTX-10 was added at a large molar crime will become more active in this area. excess (dashed lines), the cell labeling was largely abrogated. 0005. Furthermore, biologics are sensitive to environmen Control peptides had no effect (not shown). The shaded his tal conditions and improper storage or handling at any point in togram represents CLL cells incubated with fluorescently the Supply chain. Improper handling of a biologic. Such as an labeled normal human IgG. antibody, could reduce or inactivate their ability to bind the 0013 FIG.3 illustrates one embodiment of the lateral flow target antigen and mitigate their therapeutic effect. At present, immunoassay design and development path. The flow chart there are no routine safeguards in place at the time of admin istration to ensure that a patient is receiving the correct, active shows the design process for a lateral flow immunoassay. therapy. 0014 FIG. 4 illustrates one embodiment of mimetope LFA for bevacizumab, trastuzumab, and rituximab. The 0006 Thus, a need remains to develop simple, rapid sample comprising an antibody flows through a conjugatepad assays that Verifies both the presence and integrity of appro loaded with goat anti-human IgG attached to colloidal gold, priate antibody in the sample and that are amenable for use at then onto a membrane striped with the appropriate mimetope any point in the Supply chain, including bedside. Such an peptide, and finally an assay control. A false positive on one assay will provide patients and their physicians an extra anti-lambda test line is shown by an asterisk. degree of confidence that the correct, active therapeutic is (0015 FIG.5 illustrates that the lateral flow assay disclosed administered. herein has wide dynamic range. Samples tested were Ritux imab at 0.0 mg/ml (negative control), 0.01 mg/ml, 0.1 mg/ml. SUMMARY OF THE INVENTION 1.0 mg/ml, and 10 mg/ml (vial concentration). With increas 0007 Disclosed herein is a test device for determining the ing Rituximab concentration, the test line gets more intense. presence or integrity of a biologic comprising a sample pad 0016 FIG. 6 further illustrates that the lateral flow assay for receiving the biologic, a conjugate pad, and a test mem disclosed herein has a wide dynamic range. FIG. 6 shows one brane comprising at least one test line comprising an immo embodiment of the sandwich lateral flow assay with two test bilized mimetope. lines. The test lines comprise peptide mimetope striped at two 0008 Disclosed herein is a method of determining the different concentrations on the membrane. Samples tested are integrity of a biologic comprising (a) contacting the biologic Rituximab at 0.0 mg/ml (negative control), 0.01 mg/ml, 0.1 with a test device, wherein the test device comprises a sample mg/ml, 1.0 mg/ml, and 10 mg/ml (vial concentration). With pad for receiving the biologic, a conjugate pad, a test mem increasing Rituximab concentration, the lower test line gets brane comprising at least one test line comprising an immo less intense whereas the upper test line gets more intense. US 2015/029.3086 A1 Oct. 15, 2015 DETAILED DESCRIPTION OF THE (IgA1 and IgA2), Igl), IgE. IgM, and IgG (IgG1, IgG3 and EMBODIMENTS IgG4) etc. In some embodiments, the antibody is polyclonal 0017. The terminology used herein is for the purpose of or monoclonal. In some embodiments, the antibody is from describing particular embodiments only and is not intended to any origin, such as mouse or human, including a chimeric be limiting of the invention. As used herein, the singular antibody thereof. In some embodiments, the antibody is forms “a,” “an,” and “the' are intended to include the plural humanized. forms as well, unless the context clearly indicates otherwise. (0023 Examples of antibodies include, but are not limited Furthermore, to the extent that the terms “including.” “includes,” “having.” “has.” “with.” or variants thereof are to, bevacizumab, trastuzumab, rituximab, abciximab, adali used in either the detailed description and/or the claims, such mumab, alemtuzumab, basiliximab, belimumab, brentux terms are intended to be inclusive in a manner similar to the imab vedotin, canakinumab, cetuximab, certolizumab pegol, term “comprising.” daclizumab, denosumab, eculizumab, efalizumab, gemtu 0018.
Load more

Recommended publications
  • 1 Therapeutic Antibodies – from Past to Future Stefan Dubel¨ and Janice M
    1 1 Therapeutic Antibodies – from Past to Future Stefan Dubel¨ and Janice M. Reichert 1.1 An Exciting Start – and a Long Trek In the late nineteenth century, the German army doctor Emil von Behring (1854–1917), later the first Nobel Laureate for Medicine, pioneered the thera- peutic application of antibodies. He used blood serum for the treatment of tetanus and diphtheria (‘‘Blutserumtherapie’’). When his data were published in 1890 [1], very little was known about the factors or mechanisms involved in immune defense. Despite this, his smart conclusion was that a human body needs some defense mechanism to fight foreign toxic substances and that these substances should be present in the blood – and therefore can be prepared from serum and used for therapy against toxins or infections. His idea worked, and the success allowed him to found the first ‘‘biotech’’ company devoted to antibody-based therapy in 1904 – using his Nobel Prize money as ‘‘venture capital.’’ The company is still active in the business today as part of CSLBehring. In 1908, Paul Ehrlich, the father of hematology [2] and the first consistent concept of immunology (‘‘lateral chain theory,’’ Figure 1.1d [3]), was awarded the second Nobel Prize related to antibody therapeutics for his groundbreaking work on serum, ‘‘particularly to the valency determination of sera preparations.’’ Ehrlich laid the foundations of antibody generation by performing systematic research on immunization schedules and their efficiency, and he was the first to describe different immunoglobulin subclasses. He also coined the phrases ‘‘passive vaccination’’ and ‘‘active vaccination.’’ His lateral chain theory (‘‘Seitenketten,’’ sometimes misleadingly translated to ‘‘side-chain theory’’) postulated chemical receptors produced by blood cells that fitted intruding toxins (antigens).
    [Show full text]
  • Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens
    Int. J. Mol. Sci. 2012, 13, 8273-8292; doi:10.3390/ijms13078273 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens Nicola Clementi *,†, Nicasio Mancini †, Laura Solforosi, Matteo Castelli, Massimo Clementi and Roberto Burioni Microbiology and Virology Unit, “Vita-Salute” San Raffaele University, Milan 20132, Italy; E-Mails: [email protected] (N.M.); [email protected] (L.S.); [email protected] (M.C.); [email protected] (M.C.); [email protected] (R.B.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-2-2643-5082; Fax: +39-2-2643-4288. Received: 16 March 2012; in revised form: 25 June 2012 / Accepted: 27 June 2012 / Published: 4 July 2012 Abstract: In the last two decades, several phage display-selected monoclonal antibodies (mAbs) have been described in the literature and a few of them have managed to reach the clinics. Among these, the anti-respiratory syncytial virus (RSV) Palivizumab, a phage-display optimized mAb, is the only marketed mAb directed against microbial pathogens. Palivizumab is a clear example of the importance of choosing the most appropriate strategy when selecting or optimizing an anti-infectious mAb. From this perspective, the extreme versatility of phage-display technology makes it a useful tool when setting up different strategies for the selection of mAbs directed against human pathogens, especially when their possible clinical use is considered.
    [Show full text]
  • Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: a Free Assay Disguised As Total
    pharmaceutics Article Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total John Hood 1,*, Ignacio González-García 1 , Nicholas White 1, Leeron Marshall 1,2, Vincent F. S. Dubois 1 , Paolo Vicini 1,3 and Paul G. Baverel 1,4 1 Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge CB21 6GH, UK; [email protected] (I.G.-G.); [email protected] (N.W.); [email protected] (L.M.); [email protected] (V.F.S.D.); [email protected] (P.V.); [email protected] (P.G.B.) 2 Salford Royal Foundation Trust, Salford M6 8HD, UK 3 Confo Therapeutics, 9052 Ghent, Zwijnaarde, Belgium 4 Roche Pharma Research and Early Development, Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland * Correspondence: [email protected]; Tel.: +44-1223-749-6288 Abstract: A sequential pharmacokinetic (PK) and pharmacodynamic (PD) model was built with Nonlinear Mixed Effects Modelling based on data from a first-in-human trial of a novel biologic, MEDI7836. MEDI7836 is a human immunoglobulin G1 lambda (IgG1λ-YTE) monoclonal antibody, Citation: Hood, J.; González-García, with an Fc modification to reduce metabolic clearance. MEDI7836 specifically binds to, and function- I.; White, N.; Marshall, L.; Dubois, ally neutralizes interleukin-13. Thirty-two healthy male adults were enrolled into a dose-escalation V.F.S.; Vicini, P.; Baverel, P.G. clinical trial. Four active doses were tested (30, 105, 300, and 600 mg) with 6 volunteers enrolled Pharmacokinetic-Pharmacodynamic per cohort. Eight volunteers received placebo as control.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 April 2020 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 April 2020 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 4A Standard for CBD products 10 5 Pharmacist may dilute medicine in particular case 11 6 Colouring substances [Revoked] 11 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Structure, Function, and Therapeutic Use of Igm Antibodies
    antibodies Review Structure, Function, and Therapeutic Use of IgM Antibodies Bruce A. Keyt *, Ramesh Baliga, Angus M. Sinclair, Stephen F. Carroll and Marvin S. Peterson IGM Biosciences Inc, 325 East Middlefield Road, Mountain View, CA 94043, USA; [email protected] (R.B.); [email protected] (A.M.S.); [email protected] (S.F.C.); [email protected] (M.S.P.) * Correspondence: [email protected]; Tel.: +1-650-265-6458 Received: 16 September 2020; Accepted: 9 October 2020; Published: 13 October 2020 Abstract: Natural immunoglobulin M (IgM) antibodies are pentameric or hexameric macro- immunoglobulins and have been highly conserved during evolution. IgMs are initially expressed during B cell ontogeny and are the first antibodies secreted following exposure to foreign antigens. The IgM multimer has either 10 (pentamer) or 12 (hexamer) antigen binding domains consisting of paired µ heavy chains with four constant domains, each with a single variable domain, paired with a corresponding light chain. Although the antigen binding affinities of natural IgM antibodies are typically lower than IgG, their polyvalency allows for high avidity binding and efficient engagement of complement to induce complement-dependent cell lysis. The high avidity of IgM antibodies renders them particularly efficient at binding antigens present at low levels, and non-protein antigens, for example, carbohydrates or lipids present on microbial surfaces. Pentameric IgM antibodies also contain a joining (J) chain that stabilizes the pentameric structure and enables binding to several receptors. One such receptor, the polymeric immunoglobulin receptor (pIgR), is responsible for transcytosis from the vasculature to the mucosal surfaces of the lung and gastrointestinal tract.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Structural Basis for Nonneutralizing Antibody Competition at Antigenic
    Structural basis for nonneutralizing antibody PNAS PLUS competition at antigenic site II of the respiratory syncytial virus fusion protein Jarrod J. Mousaa, Marion F. Sauerb, Alexander M. Sevyb, Jessica A. Finnc, John T. Batesa, Gabriela Alvaradoc, Hannah G. Kinga, Leah B. Loerinca, Rachel H. Fongd, Benjamin J. Doranzd, Bruno E. Correiae, Oleksandr Kalyuzhniye, Xiaolin Wenf, Theodore S. Jardetzkyf, William R. Schiefe, Melanie D. Ohig, Jens Meilerh, and James E. Crowe Jr.a,c,i,1 aVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232; bChemical and Physical Biology Program, Vanderbilt University Medical Center, Nashville, TN 37232; cDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN 37232; dIntegral Molecular, Inc., Philadelphia, PA 19104; eDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037; fDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305; gDepartment of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN 37232; hDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232; and iDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232 Edited by Rino Rappuoli, GSK Vaccines, Siena, Italy, and approved September 20, 2016 (received for review June 10, 2016) Palivizumab was the first antiviral monoclonal antibody (mAb) rearrangement, resulting in fusion of the viral and cell mem- approved for therapeutic use in
    [Show full text]
  • Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: a Noninferiority Trial
    ARTICLES Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial AUTHORS: Xavier Carbonell-Estrany, MD, PhD,a Eric A. F. WHAT’S KNOWN ON THIS SUBJECT: Monthly prophylaxis with Simo˜es, MD, MB, BS, DCH,b,c Ron Dagan, MD,d Caroline B. palivizumab has been shown to reduce RSV hospitalizations by Hall, MD,e Brian Harris, MS,f Micki Hultquist, MS,f Edward ϳ50% overall compared with placebo in children at high risk for f f M. Connor, MD, and Genevieve A. Losonsky, MD, for the severe RSV disease. Motavizumab, a monoclonal antibody Motavizumab Study Group developed from palivizumab, has enhanced preclinical activity aNeonatology Service, Hospital Clínic, Agrupacio´Sanite`ria Clínic, against RSV. Hospital de Sant Joan de De´u, Barcelona, Spain; bDepartment of Pediatrics, University of Colorado School of Medicine, Denver, Colorado; cDivision of Infectious Diseases, Children’s Hospital, WHAT THIS STUDY ADDS: Motavizumab may offer an improved Denver, Colorado; dPediatric Infectious Disease Unit, Soroka alternative in prophylaxis for serious RSV disease in children at University Medical Center and Faculty of Health Sciences, Ben- high risk. Motavizumab was noninferior to palivizumab for Gurion University, Beer-Sheva, Israel; eDepartments of Pediatrics prevention of RSV hospitalization (primary end point) and and Medicine, University of Rochester Medical Center, superior to palivizumab for reduction of RSV-specific outpatient Rochester, New York; and fMedImmune, Gaithersburg, Maryland MALRI (a secondary end point). KEY WORDS clinical trial, motavizumab, palivizumab, pediatric, respiratory infection, respiratory syncytial virus ABBREVIATIONS RSV—respiratory syncytial virus CLD—chronic lung disease of prematurity abstract MALRI—medically attended lower respiratory tract infection OBJECTIVE: Palivizumab reduces respiratory syncytial virus (RSV) hospi- OM—otitis media ϳ AE—adverse event talization in children at high risk by 50% compared with placebo.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • List Item Synagis-H-C-257-P46-0036 : EPAR
    21 November 2013 EMA/CHMP/780068/2013 Committee for Medicinal Products for Human Use (CHMP) Synagis (Palivizumab) Procedure no. EMA/H/C/000257/P46/036 CHMP assessment report for paediatric use studies submitted according to Article 46 of the Regulation (EC) No 1901/2006 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Introduction On July 30, 2013, the MAH submitted seven completed paediatric studies for palivizumab, in accordance with Article 46 of Regulation (EC) No1901/2006, as amended. A short critical expert overview for each study has also been provided. The MAH states that four of the submitted paediatric studies (M12-420, W10-664, MI-CP118, MI- CP127) do not influence the benefit risk for palivizumab and that no consequential regulatory action is required. Studies MI-CP116, MI-CP110 and MI-CP124 will be submitted as supportive clinical experience in an extension application consisting of the full relevant data package to register the solution for injection formulation in the EU; expected to be submitted by October 2013. Scientific discussion Information on the development program The MAH stated that: Study M12-420, Multi-center, Open-label, Uncontrolled Clinical Study of
    [Show full text]